{"Clinical Trial ID": "NCT01202591", "Intervention": ["INTERVENTION 1:", "AZD4547 80mg bd Cont + Ex 25mg", "80 mg AZD4547 BD continuous + 25 mg exemestane", "INTERVENTION 2:", "AZD4547 40mg Cont + Ex 25mg", "40 mg AZD4547 BD continuous + 25 mg exemestane"], "Eligibility": ["Incorporation criteria:", "Menopausal women (either by bilateral oophorectomy or by amenorrhoea for 24 months)", "\u2022 Histological confirmation of breast cancer with documented ER+ receptor status", "Safety Run-in: Relapsing for/within 12 months after completion of a single endocrine adjuvant regimen with nonsteroidal AI and/ tamoxifen or progression after first-line endocrine therapy with nonsteroidal AL", "Rand Phase IIa: Has received at least 1 prior endocrine treatment in metastatic or relapsed media for/ within 6 months of endocrine adjuvant treatment (i.e., non-steroidal AI, tamoxifen or a combination of both). Adjuvant chemotherapy is allowed.", "Rand Phase IIa: Mandatory provision of a tumour sample to confirm polysomy or gene amplification FGFR1. At least one measurable lesion that can be accurately evaluated by CT/IRM/x-ray at baseline and follow-up visits", "- Exclusion criteria:", "A prior exposure to exemestane (safety filtration)/fulvestrant (randomised phase IIa), or any agent known to inhibit FGFR.", "More than one previous chemotherapy regimen for breast cancer", "\u00b7 ECG records that show significant abnormalities in heart rate, rhythm or conduction", "\u2022 History of hypersensitivity to the active or inactive excipients of AZD4547 or exemestane (safety fulvestant), including castor oil, or to medicinal products having a structure or chemical class similar to AZD4547 or exemestane or fulvestrant.", "Phase IIa randomised: bleeding and blood clotting conditions that would prevent the administration of fulvestrant injection into the buttocks"], "Results": ["Performance measures:", "Safety and safety in terms of number of patients with adverse events (serious and non-serious)", "[Unspecified]", "Time limit: 3 years, 10 months (recorded adverse events from screening to discontinuation of treatment and follow-up of safety for 28 days).", "Results 1:", "Title of arm/group: AZD4547 80mg bd Cont + Ex 25mg", "Description of the arm/group: 80 mg AZD4547 BD continuous + 25 mg exemestane", "Total number of participants analysed: 5", "Type of measurement: Number", "Unit of measure: Participants 5", "Results 2:", "Title of arm/group: AZD4547 40mg Cont + Ex 25mg", "Description of the arm/group: 40 mg AZD4547 BD continuous + 25 mg exemestane", "Total number of participants analysed: 5", "Type of measurement: Number", "Unit of measure: Participants 5"], "Adverse Events": ["Undesirable Events 1:", "Total: 2/5 (40.00 per cent)", "ANEMIA 0/5 (0.00 %)", "DIARRHOEA 0/5 (0.00 %)", "OESOPHAGEAL ACHALASIA 0/5 (0.00 %)", "STOMATITIS 0/5 (0.00 %)", "VICE DEPOSIT NUMBER 0/5 (0.00 %)", "FLAMMATION 0/5 (0.00 %)", "DIFFUSION OF GAS 0/5 (0.00 %)", "VIRAL INFECTION 0/5 (0.00 %)", "NEUTROPENIC SEPSIS 1/5 (20.00%)", "PLEURAL INFECTION 1/5 (20.00%)", "PYELONEPHRITIS 0/5 (0.00 %)", "Adverse Events 2:", "Total: 2/5 (40.00 per cent)", "ANEMIA 1/5 (20.00 %)", "DIARRHOEA 0/5 (0.00 %)", "OESOPHAGEAL ACHALASIA 0/5 (0.00 %)", "STOMATITIS 0/5 (0.00 %)", "VICE DEPOSIT NUMBER 0/5 (0.00 %)", "FLAMMATION 0/5 (0.00 %)", "DIFFUSION OF GAS 0/5 (0.00 %)", "VIRAL INFECTION 0/5 (0.00 %)", "NEUTROPENIC SEPSIS 0/5 (0.00 %)", "PLEURAL INFECTION 0/5 (0.00 %)", "PYELONEPHRITIS 0/5 (0.00 %)"]}